← Back to home

UNRESECTABLE OR METASTATIC GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

Clinical trials for UNRESECTABLE OR METASTATIC GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA explained in plain language.

Never miss a new study

Get alerted when new UNRESECTABLE OR METASTATIC GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear

Sign up with your email to follow new studies for UNRESECTABLE OR METASTATIC GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1

New hope for hard-to-treat stomach cancer: combo therapy trial launches

Disease control Recruiting now

This study tests whether a new drug combination (iparomlimab and tuvonralimab, called QL1706) plus chemotherapy can help people with a specific type of advanced stomach cancer that cannot be removed by surgery or has spread. The cancer must be HER2-negative and have low PD-L1 lev…

Matched conditions: UNRESECTABLE OR METASTATIC GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

Phase: PHASE2 • Sponsor: Qilu Hospital of Shandong University • Aim: Disease control

Last updated May 20, 2026 11:54 UTC

UNRESECTABLE OR METASTATIC GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

Get alerted when new UNRESECTABLE OR METASTATIC GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear

New hope for hard-to-treat stomach cancer: combo therapy trial launches